Needham analyst Mike Matson upgrades Penumbra (NYSE:PEN) from Hold to Buy and announces $244 price target.
NeuroMetrix Announces Review Of Strategic Options To Promote Growth Of Its Quell Neuromodulation And DPNCheck Neurodiagnostic Businesses And To Maximize Shareholder Value
NeuroMetrix, Inc. (NASDAQ:NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a
